Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: Is it cost-effective?

被引:45
作者
Chan, YM [1 ]
Ng, TY [1 ]
Ngan, HYS [1 ]
Wong, LC [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China
关键词
SCC; cervical cancer; cost-effective;
D O I
10.1006/gyno.2001.6497
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim of this study was to assess the cost-effectiveness of serial squamous cell carcinoma antigen (SCC) monitoring in the clinical setting. Methods. All patients with squamous cell carcinoma of the cervix and SCC measurement from 1994 to 1999 were reviewed. The cost of the investigations, including blood tests, X rays, and computer tomography; and clinic visits were adjusted to 2001 dollars for all cases over the 6-year study period. The effectiveness measure was the number of cases detected by SCC monitoring before the onset of clinical symptoms or abnormal physical examination findings. Altered clinical management due to early detection was considered successful. Results. Two thousand eight hundred fifty-one SCC antigen assays were performed from 384 patients. An elevated pretreatment SCC level was associated with poorer cumulative survival over time (P < 0.05). Fifty-five patients had recurrences, with 10 local and 45 distant recurrences. SCC levels were elevated in 47 patients (85%). The median lead time was 7.8 months. The cost of finding 1 recurrence was US$4750. SCC monitoring does not alter clinical management and has no advantage over clinical examination in detecting local recurrence. Most of the recurrent diseases were detected too late for curative treatment. Only 1 patient, in whom the diagnosis could have been made by clinical examination without SCC monitoring, may have potentially benefited from exenteration. Conclusion. Posttreatment SCC monitoring is not cost-effective in the absence of curative treatment for distant spread of disease. (C) 2002 Elsevier Science.
引用
收藏
页码:7 / 11
页数:5
相关论文
共 23 条
[1]   SQUAMOUS-CELL CARCINOMA ANTIGEN (SCC-A) VALUES RELATED TO CLINICAL OUTCOME OF PREINVASIVE AND INVASIVE CERVICAL-CARCINOMA [J].
BRIOSCHI, PA ;
BISCHOF, P ;
DELAFOSSE, C ;
KRAUER, F .
INTERNATIONAL JOURNAL OF CANCER, 1991, 47 (03) :376-379
[2]  
CROMBACH G, 1989, CANCER, V63, P1337, DOI 10.1002/1097-0142(19890401)63:7<1337::AID-CNCR2820630719>3.0.CO
[3]  
2-J
[4]   CANCER OF THE UTERINE CERVIX - SENSITIVITY AND SPECIFICITY OF SERUM SQUAMOUS-CELL CARCINOMA ANTIGEN DETERMINATIONS [J].
DUK, JM ;
DEBRUIJN, HWA ;
GROENIER, KH ;
HOLLEMA, H ;
TENHOOR, KA ;
KRANS, M ;
AALDERS, JG .
GYNECOLOGIC ONCOLOGY, 1990, 39 (02) :186-194
[5]   Pretreatment serum squamous cell carcinoma antigen: A newly identified prognostic factor in early-stage cervical carcinoma [J].
Duk, JM ;
Groenier, KH ;
deBruijn, HWA ;
Hollema, H ;
tenHoor, KA ;
vanderZee, AGJ ;
Aalders, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :111-118
[6]  
KATO H, 1982, CANCER, V50, P1294, DOI 10.1002/1097-0142(19821001)50:7<1294::AID-CNCR2820500712>3.0.CO
[7]  
2-K
[8]  
KATO H, 1984, CANCER, V54, P1544, DOI 10.1002/1097-0142(19841015)54:8<1544::AID-CNCR2820540813>3.0.CO
[9]  
2-B
[10]  
KATO H, 1979, CANCER, V43, P585, DOI 10.1002/1097-0142(197902)43:2<585::AID-CNCR2820430227>3.0.CO